EBS FY 2021 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

FY 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.8B+12.4% YoY

Gross Profit

$793M44.7% margin

Operating Income

$341M19.2% margin

Net Income

$220M12.4% margin

EPS (Diluted)

$4.06

Cash Flow

Operating Cash Flow

$321M

Free Cash Flow

$96M

Stock-Based Comp.

$42M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$1.3B

Stockholders' Equity

$1.6B

Cash & Equivalents

$576M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.8B	$1.6B	+12.4%
Gross Profit	$793M	$863M	-8.1%
Operating Income	$341M	$439M	-22.1%
Net Income	$220M	$306M	-28.2%